USANA Health Sciences (NYSE:USNA – Get Free Report) and NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.
Volatility & Risk
USANA Health Sciences has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.
Earnings & Valuation
This table compares USANA Health Sciences and NRx Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| USANA Health Sciences | $854.50 million | 0.44 | $42.03 million | $0.88 | 23.25 |
| NRx Pharmaceuticals | N/A | N/A | -$25.13 million | ($2.35) | -0.88 |
USANA Health Sciences has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares USANA Health Sciences and NRx Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| USANA Health Sciences | 1.86% | 6.97% | 5.00% |
| NRx Pharmaceuticals | N/A | N/A | -395.06% |
Analyst Recommendations
This is a breakdown of current recommendations for USANA Health Sciences and NRx Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| USANA Health Sciences | 1 | 3 | 0 | 0 | 1.75 |
| NRx Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
USANA Health Sciences currently has a consensus price target of $36.00, suggesting a potential upside of 75.96%. NRx Pharmaceuticals has a consensus price target of $36.50, suggesting a potential upside of 1,663.29%. Given NRx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than USANA Health Sciences.
Institutional & Insider Ownership
54.3% of USANA Health Sciences shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 0.6% of USANA Health Sciences shares are held by company insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
USANA Health Sciences beats NRx Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
About USANA Health Sciences
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
